Detailed information for compound 505812

Basic information

Technical information
  • TDR Targets ID: 505812
  • Name: 4-[(2-cyclopropylbenzimidazol-1-yl)methyl]-N- [(1R,2S)-2-(hydroxycarbamoyl)cyclopentyl]benz amide
  • MW: 418.488 | Formula: C24H26N4O3
  • H donors: 3 H acceptors: 4 LogP: 3.14 Rotable bonds: 8
    Rule of 5 violations (Lipinski): 1
  • SMILES: ONC(=O)[C@H]1CCC[C@H]1NC(=O)c1ccc(cc1)Cn1c(nc2c1cccc2)C1CC1
  • InChi: 1S/C24H26N4O3/c29-23(26-19-6-3-4-18(19)24(30)27-31)17-10-8-15(9-11-17)14-28-21-7-2-1-5-20(21)25-22(28)16-12-13-16/h1-2,5,7-11,16,18-19,31H,3-4,6,12-14H2,(H,26,29)(H,27,30)/t18-,19+/m0/s1
  • InChiKey: FXFZIKOEGYQWSD-RBUKOAKNSA-N  

Network

Hover on a compound node to display the structore

Synonyms

  • 4-[(2-cyclopropyl-1-benzimidazolyl)methyl]-N-[(1R,2S)-2-[(hydroxyamino)-oxomethyl]cyclopentyl]benzamide

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) Starlite/ChEMBL References
Sus scrofa ADAM17 Starlite/ChEMBL References
Homo sapiens matrix metallopeptidase 1 (interstitial collagenase) Starlite/ChEMBL References
Homo sapiens matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Echinococcus multilocularis adam 17 protease Get druggable targets OG5_132656 All targets in OG5_132656
Schistosoma japonicum ko:K06059 a disintegrin and metalloproteinase domain 17, putative Get druggable targets OG5_132656 All targets in OG5_132656
Echinococcus multilocularis Blood coagulation inhibitor, Disintegrin Get druggable targets OG5_132656 All targets in OG5_132656
Schistosoma mansoni ADAM17 peptidase (M12 family) Get druggable targets OG5_132656 All targets in OG5_132656
Echinococcus granulosus adam 17 protease Get druggable targets OG5_132656 All targets in OG5_132656
Echinococcus granulosus Blood coagulation inhibitor Disintegrin Get druggable targets OG5_132656 All targets in OG5_132656
Loa Loa (eye worm) hypothetical protein Get druggable targets OG5_132656 All targets in OG5_132656

By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Echinococcus granulosus disintegrin and metalloproteinase ADAM17   112 aa 99 aa 42.4 %
Trypanosoma congolense hypothetical protein, conserved ADAM17   112 aa 100 aa 29.0 %
Brugia malayi Matrixin family protein matrix metallopeptidase 1 (interstitial collagenase) 403 aa 401 aa 27.7 %
Plasmodium yoelii A/G-specific adenine glycosylase, putative ADAM17   112 aa 109 aa 24.8 %
Echinococcus multilocularis disintegrin and metalloproteinase ADAM17   112 aa 99 aa 42.4 %
Onchocerca volvulus Putative glutaminase 3 ADAM17   112 aa 105 aa 45.7 %
Onchocerca volvulus ADAM17   112 aa 98 aa 41.8 %

Obtained from network model

Ranking Plot


Putative Targets List


Species Potential target Raw Global Species
Brugia malayi metalloprotease disintegrin 16 with thrombospondin type I motif 0.0263 0.2747 1
Echinococcus multilocularis a disintegrin and metalloproteinase with 0.0263 0.2747 0.0466
Echinococcus granulosus Blood coagulation inhibitor Disintegrin 0.0294 0.3511 0.147
Echinococcus multilocularis Blood coagulation inhibitor, Disintegrin 0.0294 0.3511 0.147
Echinococcus multilocularis adam 17 protease 0.0557 1 1
Echinococcus granulosus a disintegrin and metalloproteinase with 0.0263 0.2747 0.0466
Onchocerca volvulus Matrix metalloproteinase homolog 0.0152 0 0.5
Schistosoma mansoni ADAM17 peptidase (M12 family) 0.0557 1 1
Loa Loa (eye worm) matrixin family protein 0.0165 0.0337 0.0961
Onchocerca volvulus Matrilysin homolog 0.0152 0 0.5
Loa Loa (eye worm) hypothetical protein 0.0294 0.3511 1

Activities

Activity type Activity value Assay description Source Reference
CL (ADMET) = 1.5 L/hr.Kg Clearance in Sprague-Dawley rat at 5.0 mg/kg, iv ChEMBL. 18242982
F (ADMET) = 22 % Oral bioavailability in Sprague-Dawley rat at 8.0 mg/kg ChEMBL. 18242982
IC50 (binding) = 2.7 nM Inhibition of semi purified pig TACE ChEMBL. 18242982
IC50 (binding) = 2.7 nM Inhibition of semi purified pig TACE ChEMBL. 18242982
IC50 (functional) = 54 nM Reduction of LPS-induced TNFalpha in human whole blood ChEMBL. 18242982
IC50 (functional) = 54 nM Reduction of LPS-induced TNFalpha in human whole blood ChEMBL. 18242982
Ki (binding) > 2128 nM Inhibition of MMP9 (unknown origin) ChEMBL. 18242982
Ki (binding) > 2128 nM Inhibition of MMP9 (unknown origin) ChEMBL. 18242982
Ki (binding) > 3333 nM Inhibition of MMP2 (unknown origin) ChEMBL. 18242982
Ki (binding) > 3333 nM Inhibition of MMP2 (unknown origin) ChEMBL. 18242982
Ki (binding) > 4948 nM Inhibition of MMP1 (unknown origin) ChEMBL. 18242982
Ki (binding) > 4948 nM Inhibition of MMP1 (unknown origin) ChEMBL. 18242982
Papp (ADMET) = 2 10^-6 cm/s Apparent permeability across human Caco2 cells ChEMBL. 18242982
Papp (ADMET) = 2 10^-6 cm/s Apparent permeability across human Caco2 cells ChEMBL. 18242982

Phenotypes

Whole-cell/tissue/organism interactions

Species name Source Reference Is orphan
Homo sapiens ChEMBL23 18242982

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.